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This aim of this study was to validate the Scalpdex, a 
quality of life questionnaire for adults with scalp der-
matitis, in children with scalp psoriasis. The reliability, 
responsiveness and validity of the 3 scales (symptoms, 
functioning and emotions) of this 22-item questionnaire 
were analysed in a cohort of children with scalp psoriasis 
(age range 6–18 years). A total of 94 children completed 
the questionnaire once, and 53 children a second time, 
after treatment of their scalp psoriasis. The Children’s 
Scalpdex in Psoriasis (CSP) demonstrated reliability 
with internal consistency (Cronbach’s α, 0.69–0.91). The 
CSP scales proved sensitive to change in the expected 
direction for children whose scalp psoriasis improved. 
Moderate effect sizes were observed between both visits 
for all 3 scales of the CSP (Cohen’s d, 0.44–0.58). In con-
clusion, the CSP is a reliable, responsive and valid ques-
tionnaire, which is the first to illustrate the specific influ-
ence of scalp psoriasis on quality of life in children. Key 
words: scalp psoriasis; children; questionnaire; quality of 
life assessment.
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In children, the scalp is a predilection site for psoriasis, 
and studies have demonstrated that the scalp is most 
often the initial site affected (1–4). Scalp involvement 
is reported in 47.0–88.9% of all children with psoriasis 
(5–8). Involvement of the scalp can be a particular burden 
for patients with psoriasis because of the visibility of the 
lesions, and it is difficult to apply therapy (9). Chen et 
al. (10) developed and validated the Scalpdex, a quality 
of life (QoL) questionnaire specifically for adults with 
scalp dermatitis (psoriasis and seborrhoeic dermatitis). 
This instrument can be used to determine which aspect of 
scalp dermatitis bothers patients the most, and to evaluate 
the influence of therapeutic intervention on QoL.
The impact of scalp psoriasis on QoL, especially in 
children with psoriasis, has not been investigated. Al-
though a skin-specific questionnaire exists to measure 
QoL in children with skin diseases of the whole body 
(Children’s Dermatology Life Quality Index, CDLQI) 
(11), there is no specific instrument to assess the influ-
ence of scalp psoriasis on QoL in children. 
This study aims to validate the Scalpdex in children 
with scalp psoriasis. The Children’s Scalpdex in Psoria-
sis (CSP) was assessed for its reliability, responsiveness 
and validity. The validation of an additional QoL ques-
tionnaire for children with scalp psoriasis will make it 
possible to focus on the symptoms and emotional and 
psychological impact of scalp psoriasis in children and 
to assess the influence of treatments. 
MATERIALS AND METHODS
Instrument development
The content of the CSP questions was based on the validated 
Scalpdex questionnaire (10). The Scalpdex was developed based 
on focus sessions with adult patients with scalp psoriasis and 
seborrhoeic dermatitis. Fourteen scalp dermatitis-specific items 
were formulated from these in-depth interviews, and 9 items from 
the Skindex were included (12). The questionnaire comprised 23 
items, which were clustered and tested by factor analyses into 
3 scales, labelled “symptoms”, “functioning” and “emotions”. 
For the CSP, the Scalpdex items were translated into Dutch 
and discussed in a steering group, comprising 2 dermatologists, 
1 paediatric dermatologist and one psychologist with a broad 
expertise in questionnaires for children with psoriasis. When 
necessary, the questions were modified slightly in order to make 
them more comprehensive for children. The item; “The cost of 
caring for my scalp condition bothers me”, was not included, 
because the steering group agreed that children are unlikely 
to be concerned about this topic. The CSP thus comprises 22 
items, which consist of 3 major constructs, “symptoms”, “fun-
ctioning” and “emotions”, which is in line with the original 
Scalpdex. All items enquired about the past 4 weeks. Respon-
ses to the questions were based on a 5-point Likert-type scale 
(“never” = 0, “rarely” = 25, “sometimes” = 50, “often” = 75, and 
“all the time” = 100). A lower score represents a better QoL. The 
responses to item 19, “I feel that my knowledge about caring 
for my scalp psoriasis is adequate”, were reverse scored. Scale 
scores were the mean of responses to items in a given scale. If 
necessary, patients aged between 6 and 12 years were allowed 
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to complete the questionnaire with the help of the child’s parent 
or guardian. The CSP takes 5–10 min to complete. 
Sample population
The department of dermatology of Radboud University Nij-
megen Medical Centre has a prospective observational juvenile 
psoriasis cohort (< 18 years) from daily clinical practice, called 
the Child-CAPTURE (Continuous Assessment of Psoriasis 
Treat ment Use Registry). All of the children aged between 6 
and 18 years who visited the department between March 2011 
and May 2012 with more than 5% scalp area involvement com-
pleted the questionnaire at baseline. Patients were treated for 
their scalp psoriasis according to the physician’s opinion. The 
following patient characteristics were recorded: age, gender, 
age at onset, family history and duration of psoriasis.
Outcome measures
At baseline, and if applicable at a second visit, the 22 items of 
the CSP were completed (range 0–100). In addition, patient’s 
QoL was evaluated with the validated Dutch version of the 
Children’s Dermatology Life Quality Index, CDLQI (10 items; 
range 0–30) (11, 13). For both questionnaires, higher scores in-
dicate worse QoL. It is hypothesized that the CSP is better than 
the CDLQI questionnaire to assess the explicit impact of scalp 
psoriasis on QoL in children. Severity of scalp psoriasis was 
established by the Physician Global Assessment of the Scalp 
(PhGA scalp; range 0–5) and Patient Global Assessment of the 
Scalp (PaGA scalp; range 0–5). Clinical severity of psoriasis of 
the whole body was assessed by a clinician using the Psoriasis 
Area and Severity Index (PASI; range 0–72) (14).
Statistical analyses
The CSP was tested for reliability, responsiveness and validity. 
Reliability was assessed by Cronbach’s α at scale level. This 
expresses internal consistency; whether the items in the scale 
are correlated, and thus are measuring the same concept. A 
Cronbach’s α coefficient ≥ 0.70 is considered acceptable (15). 
For construct validity, first confirmatory factor analysis was 
performed to test whether the 3 constructs of the Scalpdex 
(symptoms, functioning and emotions) are similar in the CSP. 
Thereafter, the correlations between the mean scale scores of 
the CSP and the CDLQI and the scalp psoriasis severity scores 
by patient and physician were examined using Spearman’s rank 
correlation coefficient. It was hypothesized that CSP would be 
positively correlated with all the different scalp psoriasis severity 
scores and have higher correlations than the CDLQI with the scalp 
severity scores. For the discriminant validity, we hypothesized 
that the CDLQI, a skin-specific questionnaire for the whole body, 
is not sensitive enough to measure responsiveness over time for 
changes in the QoL specific to scalp psoriasis. Cohen’s D was 
calculated for responsiveness of both the CSP and the CDLQI. 
Responsiveness of the CSP and CDLQI questionnaires was tested 
by calculating the change in the mean scale scores (symptoms, 
functioning and emotions) of the CSP and the change in total 
CDLQI of the patients who completed the questionnaire twice. 
Cohen’s D was used to calculate within-group effect sizes, to 
indicate the standardized differences between 2 means at the 
2 occasions, before and after treatment of the scalp psoriasis, 
for both the CSP and the CDLQI. Cohen’s d is defined as the 
difference between 2 means, divided by the standard deviation 
(SD). A Cohen’s D of 0.2 was considered to indicate a small 
effect, 0.5 to indicate a medium effect, and effects higher than 
0.8 to indicate large effects (16). The paired t-test was applied 
to the baseline answers and the answers of the second time-point 
for 3 groups: those who improved according to the opinion of 
the physician (PhGA scalp) or their own opinion (PaGA scalp); 
those who showed no change in their scalp psoriasis, and those 
whose scalp conditioned worsened. Statistical analyses were 
performed in SPSS software 18.0 (SPSS Inc., Chicago, IL, USA) 
and Mplus version 6.11. 
RESULTS
Study sample
Patient characteristics of the study cohort are shown 
in Table I. A total of 94 children, mean age 12.4 ± 3.3 
years, with scalp psoriasis completed the questionnaire 
once. The majority of patients were female (59.6%). 
Patients had a mean duration of psoriasis of 3.7 ± 3.5 
years and a mean psoriasis severity (PASI) of 4.8 ± 2.8. 
Both patients (PaGA scalp) and physician (PhGA scalp) 
reported a median scalp psoriasis severity of 2 (range 
1–5). Fifty-three patients completed the questionnaire 
a second time. 
Item analysis
Mean ±SD item scores of the CSP demonstrated that the 
following 3 items were most affected (Table II): “I am 
bothered by the persistence/reoccurrence of my scalp 
psoriasis” (55.3 ± 33.4), “My scalp psoriasis itches” 
(52.9 ± 31.5) and “I feel that my knowledge about ca-
ring for my scalp psoriasis is adequate” (51.9 ± 34.0). 
The item with the lowest mean score was the question: 
“My scalp psoriasis affects the colour of clothes I wear” 
(9.8 ± 20.2). In Table II the mean scores of all items are 
listed. In 8 out of 22 CSP items (36.4%) vs. 8 out of 
10 CDLQI items (80%), at least 50% of the patients 
answered never.
Reliability
Internal consistency reliability of the 3 scales was ana-
lysed with Cronbach’s α. For all the 3 scales the internal 
consistency was relatively high (“symptoms” = 0.69; 
“functioning” =0.74, “emotions” = 0.91). 
Construct validity
Confirmative factor analysis demonstrated an accep-
table fit for the 3-factor model. This indicates that the 
Table I. Patient characteristics (n=94)
Variables
Age, years, mean ± SD (range) 12.4 ± 3.3 (6–17) 
Gender, boys/girls, n (%) 38/56 (40.4/59.6)
Psoriasis history mean ± SD (range)
Age at onset, years 8.3 ± 4.2 (0–17)
Duration of psoriasis, years 3.7 ± 3.5 (0–13)
Psoriasis baseline assessments scores
PASI, mean ± SD 4.8 ± 2.8
Physician Global Assessment Scalp, median (range) 2 (1–5)
Patient Global Assessment Scalp, median (range) 2 (1–5)
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3 scales of the Scalpdex (symptoms, functioning and 
emotions) can also be used in our CSP. Correlations 
were calculated between the scale scores of the CSP 
and the scores of scalp psoriasis severity, PhGA and 
PaGA (Table III). The highest significant positive corre-
lations for all scales were demonstrated between PaGA 
scalp and the 3 scales; symptoms r = 0.51 (p < 0.001), 
functioning r = 0.46 (p < 0.001) and emotions r = 0.46 
(p < 0.001). PhGA scalp also showed significant posi-
tive correlations with the 3 scales; symptoms r = 0.44 
(p < 0.001), functioning r = 0.32 (p = 0.002), and emo-
tions r = 0.27 (p = 0.009). The CDLQI correlated less 
significantly positively with both PhGA scalp (r = 0.21; 
p = 0.05) and PaGA scalp (r = 0.30; p = 0.004) compared 
with the CSP scales.
Responsiveness and discriminant validity
A total of 53 patients completed the questionnaire a 
second time and were analysed for responsiveness. 
Because patients were seen in daily clinical practice, the 
period of time between the first and second visit varied 
between 1 and 7 months (mean ± SD; 4.3 ± 1.8). First, 
effect sizes with Cohen’s D were calculated between the 
2 time-points for both CSP and CDLQI. Cohen’s D for 
CSP showed moderate effect sizes (symptoms = 0.44; 
functioning = 0.58 and emotions = 0.51), whereas no ef-
fect size was found for the CDLQI (Cohen’s D = –0.03).
To evaluate the responsiveness of the CSP and the 
CDLQI with respect to changes in severity of scalp 
psoriasis, patients were divided into 3 groups. The first 
group consisted of patient with a worsening of their scalp 
psoriasis, either according to the physician (Table IV), 
or according to the patient’s own opinion (Table V). The 
second and third group reported no change in severity 
or an improvement in their scalp psoriasis, respectively. 
Significant changes in all 3 scales of the CSP were found 
in the group with an improvement in their scalp psoria-
sis (p ≤ 0.001). This effect was found in improvements 
based on both PhGA and PaGA with a moderate size 
effect, Cohen’s D between 0.66 and 0.98. Patients with 
worsening of the scalp condition based on alterations in 
PhGA scalp showed a significant increase in mean score 
for the scale “symptoms” (14.6 ± 13.8; p = 0.004), but 
not for the other 2 scales. It is notable that patients with 
the same scalp condition at both visits based on PhGA 
scalp showed a significant improvement for the emotions 
scale (–9.3 ± 11.0). All other alterations in both PaGA 
and PhGA scalp and the other scales demonstrated no 
significant increase or decrease in mean scores. 
Interestingly, for patients in whom scalp psoriasis 
improved from both the physician and the patient’s point 
of view (Tables IV and V) the skin-specific CLDQI 
questionnaire showed a significant increase in mean 
total CDLQI score (more impairment in QoL) (Table IV, 
n = 26, PhGA scalp: ΔCDLQI 3.3 ± 5.1, p = 0.03; Table 
V, n = 27, PaGA scalp: ΔCDLQI 2.5 ± 5.7, p = 0.03). 
Because of this, we analysed the course of psoriasis 
severity on other parts of the body for the patients in 
whom the scalp psoriasis improved. Surprisingly, the 
psoriasis severity of the entire body, expressed by the 
PASI, increased in this group (PhGA scalp: ΔPASI 
3.1 ± 4.2, p = 0.001; PaGA scalp: ΔPASI 3.2 ± 4.7, 
p = 0.001), whilst the scalp psoriasis improved.
DISCUSSION
The results of this study show that the CSP is a relia-
ble, responsive and valid questionnaire. It is the first 
Table II. Mean score of the items of the Children’s Scalpdex in 




1. My scalp psoriasis hurts S 23.9 ± 26.7
2. My scalp psoriasis makes me feel sad E 23.1 ± 27.5
3. My scalp psoriasis itches S 52.9 ± 31.5c
4. I am ashamed of my scalp psoriasis E 28.2 ± 31.2
5. I am embarrassed by my scalp psoriasis E 14.9 ± 23.6
6. I am angry/frustrated by my scalp psoriasis E 28.5 ± 29.6
7. I am humiliated by my scalp psoriasis E 13.8 ± 23.7
8. My scalp psoriasis bleeds S 26.1 ± 26.9
9. I am annoyed by my scalp psoriasis E 43.1 ± 36.7
10. I am bothered by the appearance of my scalp 
psoriasis
E 31.4 ± 32.8
11. My scalp psoriasis makes me feel self-conscious E 17.3 ± 24.6
12. I am bothered that my scalp psoriasis is incurable E 41.5 ± 35.3
13. My scalp psoriasis affects how to wear my hair 
(hairstyle, hats)
F 20.7 ± 31.2
14. I am bothered by people’s questions about my 
scalp psoriasis
E 34.0 ± 30.2
15. My scalp psoriasis affects the colour of clothes I 
wear
F 9.8 ± 20.2
16. I am bothered by the persistence/reoccurrence of 
my scalp psoriasis
E 55.3 ± 33.4c
17. I feel stressed about my scalp psoriasis E 12.8 ± 21.0
18. Caring for my scalp psoriasis is inconvenient for 
me
F 39.9 ± 34.8
19. I feel that my knowledge about caring for my 
scalp psoriasis is adequate
E 51.9 ± 34.0c
20. My scalp psoriasis makes my daily life difficult F 20.5 ± 25.4
21. My scalp psoriasis makes me feel different from 
others
E 22.6 ± 28.4
22. My scalp condition makes it hard to go to the 
hairdresser
F 22.3 ± 32.7
aScales: symptoms (S), emotions (E) and functioning (F). bItem scores: 0 
“never”, 25 “rarely”, 50 “sometimes”, 75 “often” and 100 “all the time”. 
cThree items with the highest mean scores.
Table III. Correlations (r) between scalp psoriasis severity scores 
and Children’s Dermatology Life Quality Index (CDLQI) and the 
Children’s in Scalpdex Psoriasis scales 
Children’s Scalpdex in Psoriasis scales
CDLQISymptoms Functioning Emotions
PhGA 0.44** 0.32** 0.27** 0.21*
PaGA 0.51** 0.46** 0.46** 0.30**
*p < 0.05; **p < 0.01. 
PhGA: Physician Global Assessment; PaGA: Patient Global Assessment.
Acta Derm Venereol 94
201Children’s Scalpdex in Psoriasis
instrument to focus on scalp psoriasis in children, illus-
trating the specific influence of scalp psoriasis on QoL. 
This QoL questionnaire makes it possible to assess the 
symptoms and emotional and psychological impact of 
paediatric scalp psoriasis. For this group of children, 
the development of this questionnaire is important for 
clinical research, decision-making and evaluation of 
therapeutic interventions. In this study the questionn-
aire was validated for children with scalp psoriasis. 
However, it is highly likely that this questionnaire can 
also be used for other paediatric scalp conditions. 
This study was performed in a juvenile psoriasis 
cohort, drawn from daily clinical practice, called the 
Child-CAPTURE (Continuous Assessment of Psoriasis 
Treatment Use Registry). This registry was set up in 
2008 and aims to record clinical and QoL data from 
children with psoriasis every time they visit our outpa-
tient clinic. For this study there was no wash-out period, 
and all patients were treated for psoriasis according to 
the physician’s opinion. Therefore, psoriasis severity at 
baseline of the study was mild. 
In our cohort of children with scalp psoriasis the items 
“my scalp itches” and “I am bothered by the persistence/
reoccurrence of my scalp condition” are the 2 items with 
the highest scores. This is in line with the original Scalp-
dex, in which Chen et al. (10) also demonstrated that 
adults with scalp dermatitis (psoriasis and seborrhoeic 
dermatitis) reported most problems with these items. In 
contrast to adults, however, children report more bleeding 
of the scalp, and are more troubled by people’s questions 
about their scalp psoriasis. On the other hand, the children 
are less embarrassed and frustrated by their scalp psoriasis 
than adults are by their scalp condition and the children 
feel that their knowledge about caring for scalp psoriasis 
is adequate, more so than the adults. The reliability of the 
CSP scales was relatively high (Cronbach’s α 0.69–0.91), 
and slightly better than the reliability reported by Chen 
et al. (10) for the Scalpdex (Cronbach’s α 0.62–0.80). 
Table IV. Mean scale scores for Children’s Scalpdex in Psoriasis and Children’s Dermatology Life Quality Index based on alterations 
in Physician Global Assessment of the scalp 
Scalp condition Scale
Scores, mean ± standard deviation
Δ (SD) p-value Cohen’s DVisit 1 Visit 2
Children’s Scalpdex in Psoriasis
Worse (n = 12) Symptoms 22.9 ± 25.4 37.5 ± 21.5 14.6 (13.8) 0.004 –0.62
Functioning 16.2 ± 22.4 19.6 ± 20.7 3.4 (11.5) 0.34 –0.16
Emotions 27.4 ± 22.2 37.1 ± 27.4 9.7 (17.2) 0.08 –0.39
Same (n = 15) Symptoms 30.6 ± 26.7 23.9 ± 22.5 –6.7 (22.3) 0.27 0.27
Functioning 17.0 ± 17.7 13.0 ± 13.9 –4.0 (11.8) 0.21 0.25
Emotions 24.5 ± 19.7 15.2 ± 16.0 –9.3 (11.0) 0.006 0.52
Better (n = 26) Symptoms 35.9 ± 17.1 19.9 ± 15.5 –16.0 (19.3) < 0.001 0.98
Functioning 20.4 ± 15.4 8.7 ± 10.3 –11.7 (13.4) < 0.001 0.89
Emotions 24.9 ± 16.0 14.5 ± 14.6 –10.4 (14.0) 0.001 0.68
Children’s Dermatology Life Quality Index
Worse (n = 12) – 5.5 ± 5.6 6.8 ± 3.9 1.3 (4.8) 0.36 –0.26
Same (n = 15) – 5.0 ± 5.3 5.4 ± 4.3 0.4 (4.4) 0.29 –0.08
Better (n = 26) – 3.5 ± 3.4 6.8 ± 4.6 3.3 (5.1) 0.03 –0.82
Significant p-values are shown in bold.
Table V. Mean scale scores for Children’s Scalpdex in Psoriasis and Children’s Dermatology Life Quality Index based on alterations 
in Patient Global Assessment of the scalp
Scalp condition Scale
Scores, mean ± standard deviation
Δ (SD) p-value Cohen’s DVisit 1 Visit 2
Children’s Scalpdex in Psoriasis 
Worse (n = 10) Symptoms 21.7 ± 26.7 31.7 ± 20.0 10.0 (18.3) 0.12 –0.42
Functioning 13.5 ± 23.6 12.5 ± 19.8 –1.0 (7.7) 0.69 0.05
Emotions 21.1 ± 22.3 26.3 ± 27.8 5.2 (16.1) 0.34 –0.21
Same (n = 16) Symptoms 29.7 ± 19.7 31.3 ± 25.0 1.6 (16.7) 0.71 –0.07
Functioning 17.8 ± 16.9 16.6 ± 14.9 –1.2 (15.9) 0.76 0.08
Emotions 25.0 ± 16.2 23.2 ± 19.8 –1.8 (13.2) 0.60 0.10
Better (n = 27) Symptoms 36.1 ± 21.4 18.8 ± 14.7 –17.3 (21.4) < 0.001 0.94
Functioning 20.7 ± 15.6 9.8 ± 12.0 –10.9 (1.8) < 0.001 0.78
Emotions 27.1 ± 18.3 15.4 ± 17.3 –11.7 (15.3) 0.001 0.66
Children’s Dermatology Life Quality Index
Worse (n = 10) – 3.6 ± 4.6 5.8 ± 4.1 2.2 (4.3) 0.14 –0.50
Same (n = 16) – 5.3 ± 4.0 6.3 ± 4.3 1.1 (3.9) 0.29 –0.24
Better (n = 27) – 4.2 ± 4.8 6.7 ± 4.5 2.5 (5.7) 0.03 –0.54
Significant p-values are shown in bold.
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Construct validity was tested by confirmative factor 
analyses. These analyses supported the 3 scales in the 
CSP, as used in the Scalpdex; namely, symptoms, func-
tioning and emotions. The scores of the 3 scales of the 
CSP showed a significant positive correlation with both 
patient- and physician-reported scalp severity; this is 
in line with the hypothesis for the construct validity. 
Interestingly, the scales have higher correlations with 
patient’s perception of the severity of the scalp psoria-
sis than with the physician’s opinion. The correlation 
between both patient- and physician-reported scalp 
severity and the CDLQI was less strong. 
Responsiveness analysis proved that the 3 scales of 
the CSP are sensitive to change in the expected direc-
tion in the children whose scalp psoriasis improved. In 
contrast to the improvement in CSP and scalp psoriasis 
of these children, the CDLQI and PASI deteriorated. 
This suggests that the CDLQI is not specific enough to 
reflect the QoL of children with scalp psoriasis. 
In conclusion, the CSP proved to be reliable, respon-
sive and valid for the assessment of QoL of children 
with scalp psoriasis. The CSP can be used as a targeted 
questionnaire in the evaluation of outcome assessments 
and the effect of therapeutic interventions on QoL in 
children with scalp psoriasis. 
The authors declare no conflicts of interest.
REFERENCES
1. Wu y, Lin y, Liu HJ, Huang CZ, Feng AP, Li JW. Childhood 
psoriasis: a study of 137 cases from central China. World 
J Pediatr 2010; 6: 260–264.
2. Nanda A, Kaur S, Kaur I, Kumar B. Childhood psoriasis: 
an epidemiologic survey of 112 patients. Pediatr Dermatol 
1990; 7: 19–21.
3. Raychaudhuri SP, Gross J. A comparative study of pediatric 
onset psoriasis with adult onset psoriasis. Pediatr Dermatol 
2000; 17: 174–178.
4. Fan X, Xiao FL, yang S, Liu JB, yan KL, Liang yH, et al. 
Childhood psoriasis: a study of 277 patients from China. J 
Eur Acad Dermatol Venereol 2007; 21: 762–765.
5. Chiam Ly, de Jager ME, Giam yC, de Jong EM, van de 
Kerkhof PC, Seyger MM. Juvenile psoriasis in European 
and Asian children: similarities and differences. Br J Der-
matol 2011; 164: 1101–1103.
6. Tollefson MM, Crowson CS, McEvoy MT, Maradit KH. 
Incidence of psoriasis in children: a population-based study. 
J Am Acad Dermatol 2010; 62: 979–987.
7. Seyhan M, Coskun BK, Saglam H, Ozcan H, Karincaoglu y. 
Psoriasis in childhood and adolescence: evaluation of demo-
graphic and clinical features. Pediatr Int 2006; 48: 525–530.
8. Stefanaki C, Lagogianni E, Kontochristopoulos G, Verra 
P, Barkas G, Katsambas A, et al. Psoriasis in children: a 
retrospective analysis. J Eur Acad Dermatol Venereol 2011; 
25: 417–421.
9. Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trueb 
RM. Scalp psoriasis: European consensus on grading and 
treatment algorithm. J Eur Acad Dermatol Venereol 2009; 
23: 1435–1444.
10. Chen SC, yeung J, Chren MM. Scalpdex: a quality-of-life 
instrument for scalp dermatitis. Arch Dermatol 2002; 138: 
803–807.
11. Lewis-Jones MS, Finlay Ay. The Children’s Dermatology 
Life Quality Index (CDLQI): initial validation and practical 
use. Br J Dermatol 1995; 132: 942–949.
12. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved 
discriminative and evaluative capability of a refined version 
of Skindex, a quality-of-life instrument for patients with 
skin diseases. Arch Dermatol 1997; 133: 1433–1440.
13. Holme SA, Man I, Sharpe JL, Dykes PJ, Lewis-Jones MS, 
Finlay Ay. The Children’s Dermatology Life Quality Index: 
validation of the cartoon version. Br J Dermatol 2003; 148: 
285–290.
14. Fredriksson T, Pettersson U. Severe psoriasis – oral therapy 
with a new retinoid. Dermatologica 1978; 157: 238–244.
15. Cortina JM. What is coefficient alpha – an examination of 
theory and applications. J Appl Psychol 1993; 78: 98–104.
16. Cohen J. Statistical power analysis for the behavioral sci-
ences. 2nd edn. Hillsdale, NJ: L. Erlbaum Associates, 1988.
Acta Derm Venereol 94
